181 related articles for article (PubMed ID: 25642445)
1. The Effect of Osteoporosis Treatments on Fatigue Properties of Cortical Bone Tissue.
Brock GR; Chen JT; Ingraffea AR; MacLeay J; Pluhar GE; Boskey AL; van der Meulen MC
Bone Rep; 2015 Jun; 2():8-13. PubMed ID: 25642445
[TBL] [Abstract][Full Text] [Related]
2. Effects of osteoporosis medications on bone quality.
Benhamou CL
Joint Bone Spine; 2007 Jan; 74(1):39-47. PubMed ID: 17196423
[TBL] [Abstract][Full Text] [Related]
3. The novel non-steroidal selective androgen receptor modulator S-101479 has additive effects with bisphosphonate, selective estrogen receptor modulator, and parathyroid hormone on the bones of osteoporotic female rats.
Furuya K; Yamamoto N; Ohyabu Y; Makino A; Morikyu T; Ishige H; Kuzutani K; Endo Y
Biol Pharm Bull; 2012; 35(7):1096-104. PubMed ID: 22791158
[TBL] [Abstract][Full Text] [Related]
4. Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone.
Acevedo C; Bale H; Gludovatz B; Wat A; Tang SY; Wang M; Busse B; Zimmermann EA; Schaible E; Allen MR; Burr DB; Ritchie RO
Bone; 2015 Dec; 81():352-363. PubMed ID: 26253333
[TBL] [Abstract][Full Text] [Related]
5. Intermittent Parathyroid Hormone After Prolonged Alendronate Treatment Induces Substantial New Bone Formation and Increases Bone Tissue Heterogeneity in Ovariectomized Rats.
Altman-Singles AR; Jeong Y; Tseng WJ; de Bakker CM; Zhao H; Lott C; Robberts J; Qin L; Han L; Kim DG; Liu XS
J Bone Miner Res; 2017 Aug; 32(8):1703-1715. PubMed ID: 28467646
[TBL] [Abstract][Full Text] [Related]
6. Medication management after intramedullary nailing of atypical fractures.
Feron JM; Cambon-Binder A
Injury; 2017 Jun; 48 Suppl 1():S15-S17. PubMed ID: 28456365
[TBL] [Abstract][Full Text] [Related]
7. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.
Ma YL; Bryant HU; Zeng Q; Schmidt A; Hoover J; Cole HW; Yao W; Jee WS; Sato M
Endocrinology; 2003 May; 144(5):2008-15. PubMed ID: 12697709
[TBL] [Abstract][Full Text] [Related]
8. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
9. Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration.
Kimura S; Saito M; Kida Y; Seki A; Isaka Y; Marumo K
Osteoporos Int; 2017 Mar; 28(3):1109-1119. PubMed ID: 27796444
[TBL] [Abstract][Full Text] [Related]
10. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.
Cheng Z; Yao W; Zimmermann EA; Busse C; Ritchie RO; Lane NE
J Bone Miner Res; 2009 Feb; 24(2):209-20. PubMed ID: 18847326
[TBL] [Abstract][Full Text] [Related]
11. A new contralateral atypical femoral fracture despite sequential therapy with teriparatide and strontium ranelate.
Nguyen HH; Milat F; Ebeling PR
Bone Rep; 2017 Jun; 6():34-37. PubMed ID: 28377979
[TBL] [Abstract][Full Text] [Related]
12. Atypical femur fracture in an adolescent boy treated with bisphosphonates for X-linked osteoporosis based on PLS3 mutation.
van de Laarschot DM; Zillikens MC
Bone; 2016 Oct; 91():148-51. PubMed ID: 27477003
[TBL] [Abstract][Full Text] [Related]
13. Atypical femoral fractures and current management.
Zheng N; Tang N; Qin L
J Orthop Translat; 2016 Oct; 7():7-22. PubMed ID: 30035084
[TBL] [Abstract][Full Text] [Related]
14. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
15. The teriparatide in the treatment of severe senile osteoporosis.
Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
[TBL] [Abstract][Full Text] [Related]
16. Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review.
Nguyen HH; van de Laarschot DM; Verkerk AJMH; Milat F; Zillikens MC; Ebeling PR
JBMR Plus; 2018 Jan; 2(1):1-11. PubMed ID: 30283886
[TBL] [Abstract][Full Text] [Related]
17. Dramatic increase in cortical thickness induced by femoral marrow ablation followed by a 3-month treatment with PTH in rats.
Zhang Q; Carlson J; Ke HZ; Li J; Kim M; Murphy K; Mehta N; Gilligan J; Vignery A
J Bone Miner Res; 2010 Jun; 25(6):1350-9. PubMed ID: 20200940
[TBL] [Abstract][Full Text] [Related]
18. Management of osteoporosis due to ovarian failure.
Eastell R
Med Pediatr Oncol; 2003 Sep; 41(3):222-7. PubMed ID: 12868123
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
